Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting around 10-20% of the population. It is most common in children, with onset in 60% of cases during the first year of life. Over the past ten years, targeted therapies have been developed to treat AD in adults in cases where ciclosporin has failed or is contraindicated. It should be noted that ciclosporin does not have marketing authorization for AD in children.
Targeted therapies for moderate to severe atopic dermatitis.
Two major types of targeted systemic therapies are available for the treatment of moderate to severe AD in adults :
- Biotherapies : represented by monoclonal antibodies targeting cytokines or their receptors.
- Small molecules : targeting specific immune pathways, such as Janus kinase inhibitors (JAKi).
Some of these therapies are also approved for use in children aged 6 months and over, with adapted dosages. These treatments are suspensory only, and must be continued over the long term, as no curative treatment for AD currently exists.
Biotherapies available in France for moderate to severe AD (immunomodulatory treatments)
Currently, two biotherapies targeting the T2 pathway have obtained marketing authorization in France for AD :
- Dupilumab (Dupixent®) : a monoclonal antibody inhibiting the interleukin 4 receptor alpha, common to the cytokines IL-4 and IL-13. It is the first biotherapy developed for moderate to severe AD in adults. Dupilumab is also approved for use in children aged 6 months and over.
- Tralokinumab (Adtralza®) : a monoclonal antibody targeting interleukin 13 (IL-13). Tralokinumab is approved for use from age 12, with the same dosage as for adults.
These biotherapies are administered by subcutaneous injection every 2 to 4 weeks.
- Lebrikizumab (Ebglyss®) : a high-affinity humanized IgG4 monoclonal antibody that binds specifically to soluble IL-13. It preferentially inhibits JAK1 or JAK1/3 signaling. It is approved for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 and over requiring systemic therapy.
- Nomolizumab (IL-31R) : not yet approved, a Phase 3 study is currently underway.
Positioning JAKi in the treatment of moderate to severe AD (new immunosuppressive treatments).
Three Janus kinase inhibitors (JAKi) have obtained marketing authorization in France for the treatment of moderate to severe AD in adults, in cases where ciclosporin has failed or is contraindicated. These treatments are administered orally on a daily basis:
- Baricitinib (Olumiant®) : Reversible selective inhibitor of JAK1 and JAK2.
- Upadacitinib (Rinvoq®) : Reversible selective JAK1 inhibitor, authorized for children aged 12 to 17 and weighing less than 30 kg, at half-dose.
- Abrocitinib (Cibinqo®) : Reversible, selective JAK1 inhibitor.
To date, there are no clear recommendations on the positioning of biotherapies versus JAK inhibitors in AD. Moreover, there are no comparative studies to show the superiority of dupilumab over tralokinumab in adults.
Biotherapies in severe asthma
The current therapeutic panel for severe asthma comprises five molecules: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab. All these biotherapies have demonstrated their efficacy in improving the control of severe asthma, with benefits such as symptom improvement, reduced exacerbations, corticosteroid sparing and improved lung function.
Their use is governed by marketing authorizations (MA), which designate them for different asthma phenotypes, whether allergic, eosinophilic, type 2 (T2) or non-T2.
Biotherapies currently available in France
- Omalizumab (anti-IgE) : used to treat severe persistent allergic asthma in patients sensitized to a pneumallergen. It is also approved for chronic spontaneous urticaria and previously-operated severe nasosinus polyposis.
- Mepolizumab (anti-IL-5) : indicated for severe eosinophilic asthma, nasosinusal polyposis and certain hypereosinophilic syndromes.
- Benralizumab (anti-IL5Ra) : prescribed for severe eosinophilic asthma, with rapid action on eosinophil depletion.
- Dupilumab (anti-IL4Ra) : targets IL-4 and IL-13 signaling pathways, used in severe asthma with type 2 inflammation, atopic dermatitis, nasosinus polyposis and eosinophilic esophagitis.
- Tezepelumab (anti-TSLP) : used as an additional background treatment for severe asthma not controlled despite inhaled corticosteroids.


